Skip to content
All Sections
Subscribe Now
74°F
Monday, September 2nd 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
74°F
Monday, September 2nd 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
High School Football
Greek Festival info ð¬ð·
Latest on RPV landslide
Shooting suspect arrested
Hot Dog on a Stick #2 closing
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
Next >
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
August 13, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Second Quarter Financial Results
July 09, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Completes Acquisition of Escient Pharmaceuticals
May 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
May 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 02, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 11, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
April 01, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
February 27, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
December 12, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
November 02, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 31, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
October 27, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close